ReviewCurrent allergy and asthma reports2012
Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.
Review in Current allergy and asthma reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Decreased flow-mediated dilatation in patients with systemic lupus erythematosus: a meta-analysis.Inflammation · 2014Pooled it
- Bifidobacterium ameliorates lupus nephritis and modulates aberrant differentiation of lymphocyte subsets.Rheumatology (Oxford, England) · 2025Article
- Lupus nephritis as an independent risk factor for carotid atherosclerosis in patients with systemic lupus erythematosus.Clinical rheumatology · 2025Article
- Endothelial function and endothelial progenitor cells in systemic lupus erythematosus.Nature reviews. Rheumatology · 2022Review
- Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers.Frontiers in immunology · 2022Review
- A Case of Systemic Lupus Erythematosus without Antiphospholipid Syndrome Causing Superior Vena Cava Syndrome.Oman medical journal · 2021Article
- MicroRNAs in Lupus Nephritis-Role in Disease Pathogenesis and Clinical Applications.International journal of molecular sciences · 2021Review
- Role of Artesunate on cardiovascular complications in rats with type 1 diabetes mellitus.BMC endocrine disorders · 2021Article
- CD40/CD40L Signaling as a Promising Therapeutic Target for the Treatment of Renal Disease.Journal of clinical medicine · 2020Review
- Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.Nature reviews. Nephrology · 2017Review
- Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis.Rheumatology (Oxford, England) · 2015Article
- Endotoxin tolerance in monocytes can be mitigated by α2-interferon.Journal of leukocyte biology · 2015Article
- Fistular onion stalk extract exhibits anti-atherosclerotic effects in rats.Experimental and therapeutic medicine · 2014Article
- Serum levels of three angiogenic factors in systemic lupus erythematosus and their clinical significance.BioMed research international · 2014Article
- Article
- Lupus nephritis: review of the literature.Current allergy and asthma reports · 2013Review
- A review on the role of quinones in renal disorders.SpringerPlus · 2013Article
- Th17/Treg imbalance induced by increased incidence of atherosclerosis in patients with systemic lupus erythematosus (SLE).Clinical rheumatology · 2013Article
- Immune response to nanomaterials: implications for medicine and literature review.Current allergy and asthma reports · 2013Review
- Role of nuclear factor-ĸB in breast and colorectal cancer.Current allergy and asthma reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In systemic lupus erythematosus (SLE) patients, the role of inflammatory mediators is relevant to the pathogenesis of accelerated atherosclerosis. CD40 ligand is increased on circulating lymphocytes, correlates with double-stranded DNA, and has an important role in predicting risk of cardiovascular disease. Vascular endothelial growth factor (VEGF) is a tightly regulated angiogenic cytokine in the kidney, and plasma levels have been associated with disease activity. It has been correlated with lupus nephritis, associated with higher mean carotid intima media thickness, and can be a novel cardiovascular risk factor in premature coronary atherosclerosis. VEGF has been demonstrated in cultured human aortic endothelial cells in the presence of simvastatin and in kidney biopsies in lupus nephritis. SLE patients have been shown to manifest disturbances in gene expression involved in lipid transport and atheroma promotion. This paper provides evidence of the immune system in accelerated atherosclerosis in SLE, the role of selected proinflammatory cytokines, and therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.